NASDAQ

Osiris restates financial reports to show $10 million loss in 2014

Osiris restates financial reports to show $10 million loss in 2014

Osiris Therapeutics Inc., a Columbia-based biotechnology firm that had its stock delisted from the Nasdaq earlier this month, said Monday it completed a previously announced restatement of 2014 financial statements to show a bigger loss than initially reported.

Osiris filed an amended annual report for 2014 showing product revenue of $50.8 million, slightly higher than a previously announced estimate of $46 million to $50 million, and a net loss of $10 million, or 29 cents per share. The company previously had reported a net loss of $1.8 million, or a loss of 5 cents per share.

The firm also said it expects to report product revenue of $89 million to $92 million for 2015 and...

43°